SIBN Stock Analysis: Si-Bone | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.125m USD | 12M Return: 35.8% | US8257041090 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.0M
Qual. Beats: 7
Rev. Trend: 99.5%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 8.1 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
SI-Bone, Inc. (NASDAQ: SIBN) is a U.S.-based medical device company founded in 2008 and headquartered in Santa Clara, California. The company specializes in procedural solutions for compromised bone, with a focus on implants designed for the sacroiliac (SI) joint. Its core product family, the iFuse system, consists of patented triangular titanium implants and related instruments used to stabilize the joint and promote bone fusion, with multiple product variants (iFuse, iFuse 3D, iFuse Bone, iFuse Torq, iFuse Bedrock Granite, and iFuse Torq TNT) serving different surgical applications.
The company sells primarily through a direct sales force supplemented by third-party sales agents and resellers, a distribution model common among specialized orthopedic device manufacturers targeting surgeons and hospitals. SI-Bone went public in October 2018 and is classified within the Health Care sector (Health Care Supplies sub-industry) as a small-cap company.
- US iFuse procedure volume growth drives top-line expansion
- CMS reimbursement coverage supports broader surgeon adoption
- New TORQ and Bedrock Granite product launches expand addressable market
| Net Income: -13.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 2.90 > 1.0 |
| NWC/Revenue: 88.39% < 20% (prev 95.23%; Δ -6.84% < -1%) |
| CFO/TA 0.02 > 3% & CFO 6.08m > Net Income -13.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.9m) vs 12m ago 3.96% < -2% |
| Gross Margin: 79.40% > 18% (prev 79.62%; Δ -0.22% > 0.5%) |
| Asset Turnover: 89.87% > 50% (prev 82.63%; Δ 7.24% > 0%) |
| Interest Coverage Ratio: -5.18 > 6 (EBIT TTM -12.6m / Interest Expense TTM 2.43m) |
| A: 0.76 (Total Current Assets 224.7m - Total Current Liabilities 29.6m) / Total Assets 256.8m |
| B: -1.80 (Retained Earnings -462.3m / Total Assets 256.8m) |
| C: -0.05 (EBIT TTM -12.6m / Avg Total Assets 245.5m) |
| D: 2.56 (Book Value of Equity 184.7m / Total Liabilities 72.1m) |
| Altman-Z'' = 1.46 = BB |
| DSRI: 1.04 (Receivables 31.5m/26.5m, Revenue 220.7m/193.6m) |
| GMI: 1.00 (GM 79.62% / 79.40%) |
| AQI: 0.61 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.14 (Revenue 220.7m / 193.6m) |
| TATA: -0.08 (NI -13.7m - CFO 6.08m) / TA 256.8m) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of November 14, 2026, the stock is trading at USD 23.44 with a total of 443,690 shares traded. Over the past week, the price has changed by -3.30%, over one month by +19.11%, over three months by +23.69% and over the past year by +35.81%.
Current recommended Stop Loss: 21.90 (which is 6.6% or 1.3 ATR below the current price).
Si-Bone has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy SIBN.
- StrongBuy: 6
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 26.8 | 14.2% |
P/S = 5.0991
P/B = 6.1313
Revenue TTM = 220.7m USD
EBIT TTM = -12.6m USD
EBITDA TTM = -3.91m USD
Long Term Debt = 35.7m USD (from longTermDebt, last quarter)
Short Term Debt = 331k USD (from shortTermDebt, last quarter)
Debt = 49.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.14m
Net Debt = -96.3m USD (calculated: Debt 49.9m - CCE 146.3m)
Enterprise Value = 1.03b USD (1.13b + Debt 49.9m - CCE 146.3m)
Interest Coverage Ratio = -5.18 (Ebit TTM -12.6m / Interest Expense TTM 2.43m)
EV/FCF = -245.3x (Enterprise Value 1.03b / FCF TTM -4.19m)
FCF Yield = -0.41% (FCF TTM -4.19m / Enterprise Value 1.03b)
FCF Margin = -1.90% (FCF TTM -4.19m / Revenue TTM 220.7m)
Net Margin = -6.20% (Net Income TTM -13.7m / Revenue TTM 220.7m)
Gross Margin = 79.40% ((Revenue TTM 220.7m - Cost of Revenue TTM 45.5m) / Revenue TTM)
Gross Margin QoQ = 79.29% (prev 79.54%)
Tobins Q-Ratio = 4.01 (Enterprise Value 1.03b / Total Assets 256.8m)
Interest Expense / Debt = 4.86% (Interest Expense 2.43m / Debt 49.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -9.94m (EBIT -12.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.58 (Total Current Assets 224.7m / Total Current Liabilities 29.6m)
Debt / Equity = 0.27 (Debt 49.9m / totalStockholderEquity, last quarter 184.7m)
Debt / EBITDA = 24.65 (negative EBITDA) (Net Debt -96.3m / EBITDA -3.91m)
Debt / FCF = 22.96 (negative FCF - burning cash) (Net Debt -96.3m / FCF TTM -4.19m)
Total Stockholder Equity = 180.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.58% (Net Income -13.7m / Total Assets 256.8m)
RoE = -7.57% (Net Income TTM -13.7m / Total Stockholder Equity 180.9m)
RoCE = -5.81% (EBIT -12.6m / Capital Employed (Equity 180.9m + L.T.Debt 35.7m))
RoIC = -4.59% (negative operating profit) (NOPAT -9.94m / Invested Capital 216.5m)
WACC = 8.09% (E(1.13b)/V(1.18b) * Re(8.28%) + D(49.9m)/V(1.18b) * Rd(4.86%) * (1-Tc(0.21)))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 99.74 | Cagr: 3.76%
[DCF] Fair Price = unknown (Cash Flow -4.19m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.09 | # QB: 7
Revenue Correlation: 99.54 | Revenue CAGR: 19.19% | SUE: 0.44 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.10 | Chg30d=+18.64% | Revisions=+40% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.34 | Chg30d=+15.27% | Revisions=+44% | GrowthEPS=+23.4% | GrowthRev=+15.5%
EPS next Year (2027-12-31): EPS=-0.29 | Chg30d=+13.18% | Revisions=+29% | GrowthEPS=+14.7% | GrowthRev=+15.5%
[Analyst] Revisions Ratio: +53% (up=10, down=2)